CL2011000100A1 - Uso de un inhibidor de desacetilasa de histona para el tratamiento de la enfermedad de hodgkin. - Google Patents

Uso de un inhibidor de desacetilasa de histona para el tratamiento de la enfermedad de hodgkin.

Info

Publication number
CL2011000100A1
CL2011000100A1 CL2011000100A CL2011000100A CL2011000100A1 CL 2011000100 A1 CL2011000100 A1 CL 2011000100A1 CL 2011000100 A CL2011000100 A CL 2011000100A CL 2011000100 A CL2011000100 A CL 2011000100A CL 2011000100 A1 CL2011000100 A1 CL 2011000100A1
Authority
CL
Chile
Prior art keywords
hodgkin
disease
treatment
histone deacetylase
deacetylase inhibitor
Prior art date
Application number
CL2011000100A
Other languages
English (en)
Spanish (es)
Inventor
Peter Wisdom Atadja
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CL2011000100A1 publication Critical patent/CL2011000100A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CL2011000100A 2008-07-18 2011-01-17 Uso de un inhibidor de desacetilasa de histona para el tratamiento de la enfermedad de hodgkin. CL2011000100A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8180508P 2008-07-18 2008-07-18

Publications (1)

Publication Number Publication Date
CL2011000100A1 true CL2011000100A1 (es) 2011-07-01

Family

ID=41128203

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2011000100A CL2011000100A1 (es) 2008-07-18 2011-01-17 Uso de un inhibidor de desacetilasa de histona para el tratamiento de la enfermedad de hodgkin.

Country Status (15)

Country Link
US (1) US20110118309A1 (enExample)
EP (1) EP2306996A1 (enExample)
JP (1) JP2011528662A (enExample)
KR (1) KR20110031980A (enExample)
CN (1) CN102099021A (enExample)
AU (1) AU2009270886A1 (enExample)
BR (1) BRPI0915927A2 (enExample)
CA (1) CA2730738A1 (enExample)
CL (1) CL2011000100A1 (enExample)
IL (1) IL210489A0 (enExample)
MA (1) MA32482B1 (enExample)
MX (1) MX2011000719A (enExample)
TW (1) TW201006470A (enExample)
WO (1) WO2010009280A1 (enExample)
ZA (1) ZA201100165B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6082737B2 (ja) * 2011-07-07 2017-02-15 リサーチ キャンサー インスティテュート オブ アメリカＲｅｓｅａｒｃｈ Ｃａｎｃｅｒ Ｉｎｓｔｉｔｕｔｅ Ｏｆ Ａｍｅｒｉｃａ がんを治療するためのシステム、方法、および製剤
US8933078B2 (en) 2011-07-14 2015-01-13 Research Cancer Institute Of America Method of treating cancer with combinations of histone deacetylase inhibitors (HDAC1) substances
WO2018157081A1 (en) 2017-02-27 2018-08-30 Research Cancer Institute Of America Compositions, methods, systems and/or kits for preventing and/or treating neoplasms
WO2018170457A1 (en) 2017-03-17 2018-09-20 Research Cancer Institute Of America Compositions, methods, systems and/or kits for preventing and/or treating neoplasms
CN109705057B (zh) * 2017-10-25 2023-05-30 成都先导药物开发股份有限公司 组蛋白去乙酰化酶抑制剂及其制备方法与用途
WO2019099750A1 (en) 2017-11-17 2019-05-23 Research Cancer Institute Of America Compositions, methods, systems and/or kits for preventing and/or treating neoplasms
WO2021092153A1 (en) * 2019-11-06 2021-05-14 Dana-Farber Cancer Institute, Inc. Selective dual histone deacetylase 6/8 (hdac6/8) degraders and methods of use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020354A1 (es) * 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
EP2034978A1 (en) * 2006-06-26 2009-03-18 Novartis AG Organic compounds
JP5784274B2 (ja) * 2006-12-04 2015-09-24 ノバルティス アーゲー Ｈｄａｃ阻害剤と代謝拮抗剤の組み合わせ

Also Published As

Publication number Publication date
TW201006470A (en) 2010-02-16
MA32482B1 (fr) 2011-07-03
EP2306996A1 (en) 2011-04-13
CA2730738A1 (en) 2010-01-21
MX2011000719A (es) 2011-03-01
KR20110031980A (ko) 2011-03-29
US20110118309A1 (en) 2011-05-19
CN102099021A (zh) 2011-06-15
AU2009270886A1 (en) 2010-01-21
JP2011528662A (ja) 2011-11-24
WO2010009280A1 (en) 2010-01-21
ZA201100165B (en) 2011-09-28
BRPI0915927A2 (pt) 2016-06-07
IL210489A0 (en) 2011-03-31

Similar Documents

Publication Publication Date Title
LTC2137143I2 (lt) Pleuromutilino dariniai, skirti mikrobų sukeltų ligų gydymui
CL2008000822A1 (es) Metodo para el tratamiento de la obesidad usando un inhibidor sglt2.
CL2012002526A1 (es) Uso de compuestos inhibidores de dpp iv de formula (i) o (ii) o una de sus sales, para el tratamiento de falla cardiaca.
EA201070786A1 (ru) Бензофуропиримидиноны
CL2009001099A1 (es) Uso de una muteina de interleuquina-2 humana para el tratamiento y/o prevencion de una enfermedad autoinmune.
GT200900315A (es) Inhibición de arni de expresión de alfa-enac
BRPI0816784A2 (pt) Fatores neuro-endócrinos para o tratamento de doenças degenerativas
CL2012000033A1 (es) Compuestos n-(3-(4as,7as)-2-amino-4a,5,7,7a-tetrahidro-4h-furo[3,4-d][1,3] tiazin-7a-il)-4- fluorofenilo) -5-fluoropiconilamida, inhibidor de bace; composicion farmaceutica que los comprende, uso del compuesto para el tratamiento de la enfermedad de alzheimer.
CR10245A (es) "nuevas combinaciones terapéuticas para el tratamiento de la depresión"
SV2011003809A (es) Derivados de heteroarilo como inhibidores de dgat1
CL2008002775A1 (es) Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
CL2008002430A1 (es) Compuestos derivados de bencenosulfonamida, inhibidores de catepsina c; composicion farmaceutica que los comprende; y su uso para el tratamiento de la epoc.
CL2008002295A1 (es) Compuestos derivados de tiazolida sustituidos con alquilsulfonilos; composicion farmaceutica; y uso para el tratamiento de la hepatitis c.
CL2007002384A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento de la psoriasis.
UY30846A1 (es) Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
CL2007002380A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento terapeutico y/o profilactico de la queratosis actinica.
BRPI0911577A8 (pt) derivados espiro-indol para o tratamento de doenças parasíticas.
HN2008001723A (es) Nitrilos espirociclicos como inhibidores de proteasa
ECSP088700A (es) Acidos 4-fenil-tiazol-5-carboxilicos y amidas de acidos 4-fenil-tiazol-5-carboxilicos como inhibidores de la plk1
CL2011000562A1 (es) Compuesto derivado de tetraciclina; util en el tratamiento de artritis reumatoide.
CL2007002388A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento de hemangiomas o hemangioblastomas.
CY1115081T1 (el) Νεο εκχυλισμα απο γαϊδουραγκαθο, μεθοδος για την παρασκευη και η χρηση του
EA201170821A1 (ru) Энзастаурин для лечения рака
EA201000069A1 (ru) Новые гербициды
BRPI0915927A2 (pt) uso de inibiodores de hdac para o tratamento da doença de hodgkin